Compare Goldman Sachs Physical Gold ETF (AAAU) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Gilead Sciences, Inc. — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.47, while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Goldman Sachs Physical Gold ETF pays none. Which is the better fit depends on your goals.
| AAAU | GILD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $155.80 |
52-Week Low | $32.74 | $110.56 |
Market Cap | — | $164.99B |
Enterprise Value | — | $188.06B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused asset, trades at $42.81, up 2.22% in the past 24 hours. Technical indicators show a bullish overall signal with strong moving average support, though oscillators suggest caution due to overbought RSI levels. Recent news highlights gold's rebound potential, with analysts citing supportive factors like central bank buying and easing Fed expectations as catalysts for further price appreciation.
The outlook for AAAU remains positive, driven by gold's strategic role amid geopolitical and fiscal uncertainties. Key risks include potential Fed policy shifts and market volatility, but institutional accumulation and bullish analyst forecasts indicate sustained investor confidence in gold's upward trajectory.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
